文献速递免疫规划传染病防控与疫情报告

单剂DNA新冠疫苗在已接种或感染成人中的安全性和持久免疫应答:一项1期研究

Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study.
PubMed 文献 · Vaccine · 2026-02-20

该开放标签1期概念验证研究评估了DNA疫苗IMNN-101在既往接种或感染SARS-CoV-2的健康成人中的安全性和免疫原性。受试者单次肌注0.5 mg、1.0 mg或2.0 mg疫苗(每组8人),67%(16/24)出现轻中度反应原性事件,未报告心肌炎或心包炎。免疫后针对XBB.1.5等流行变异株的中和抗体滴度升高2-3倍并维持6个月,显示良好安全性和持久体液免疫应答。

要点

  • 单剂IMNN-101 DNA疫苗在既往接种或感染成人中安全性良好,未报告心肌炎或心包炎。
  • 免疫后中和抗体滴度针对XBB.1.5等变异株升高2-3倍,并维持至6个月随访。

核心结论

  • PlaCCine基础DNA疫苗IMNN-101单剂接种在既往接种或感染SARS-CoV-2成人中显示良好安全性和持久体液免疫应答。

研究设计与样本

  • 开放标签1期概念验证研究,受试者为既往接种或感染SARS-CoV-2的健康成人,单次肌注0.5 mg、1.0 mg或2.0 mg IMNN-101,每组8人。

主要发现

  • 67%(16/24)受试者出现轻中度反应原性事件,包括注射部位压痛、硬结、疼痛、红斑、肿胀、瘙痒及疲劳、肌痛、头痛、恶心/呕吐。
  • 免疫后针对XBB.1.5及其他流行SARS-CoV-2变异株的中和抗体滴度升高2-3倍,并在6个月随访期间维持。

临床怎么用

  • PlaCCine疫苗热稳定、无需设备或病毒递送,为免疫接种提供了可行的替代途径。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An open label Phase-1 proof-of-concept study evaluated the safety and immunogenicity of IMNN-101, a DNA vaccine based on an expression plasmid and a synthetic delivery carrier (the PlaCCine vaccine), in healthy human adults previously vaccinated or infected with SARS-CoV-2. Study participants received a single intramuscular dose of 0.5 mg, 1.0 mg, or 2.0 mg of IMNN-101 DNA vaccine (n = 8 participants per group). Mild to moderate reactogenicity events were observed in 67% (16/24) of participants, including tenderness, hardening, pain, redness, swelling, and itching at the injection site, as well as fatigue, muscle aches, headache, and nausea/vomiting. Fourteen grade 1 or 2 treatment-emergent adverse events were reported: none of those attributed to IMNN-101. There were no reports of myocarditis or pericarditis. The immunization with IMNN-101 resulted in an increase in neutralizing antibody (NAb) titers against XBB.1.5 and other circulating variants of SARS-CoV-2, with 2-3-fold increase in NAb titers that were maintained during the 6-month follow up. This first-in-human evaluation of a PlaCCine-based DNA vaccine demonstrates a favorable safety profile and durable humoral immune response. The PlaCCine vaccine is thermostable, does not require a device or virus for delivery, and offers a viable alternative approach to immunization.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Anwer K, Musso L, Lasrado N, et al. Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study. Vaccine. 2026. PMID: 41722533. doi:10.1016/j.vaccine.2026.128357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。